Literature DB >> 34869825

A ketogenic supplement improves white matter energy supply and processing speed in mild cognitive impairment.

Maggie Roy1,2,3, Mélanie Fortier1, François Rheault3, Manon Edde3, Etienne Croteau4,5, Christian-Alexandre Castellano4, Francis Langlois1, Valérie St-Pierre1, Bernard Cuenoud6, Christian Bocti1,7, Tamas Fulop1,7, Maxime Descoteaux3, Stephen C Cunnane1,2,7.   

Abstract

INTRODUCTION: White matter (WM) energy supply is crucial for axonal function and myelin maintenance. An exogenous source of ketones, the brain's alternative fuel to glucose, bypasses the brain's glucose-specific energy deficit and improves cognitive outcomes in mild cognitive impairment (MCI). How an additional supply of ketones affects glucose or ketone uptake in specific WM fascicles in MCI has not previously been reported.
METHODS: This 6-month interventional study included MCI participants randomized to a placebo (n = 16) or ketogenic medium chain triglyceride (kMCT; n = 17) drink. A neurocognitive battery and brain imaging were performed pre- and post-intervention. WM fascicle uptake of ketone and glucose and structural properties were assessed using positron emission tomography and diffusion imaging, respectively.
RESULTS: Ketone uptake was increased in the kMCT group by 2.5- to 3.2-fold in all nine WM fascicles of interest (P < .001), an effect seen both in deep WM and in fascicle cortical endpoints. Improvement in processing speed was positively associated with WM ketone uptake globally and in individual fascicles, most importantly the fornix (r = +0.61; P = .014). DISCUSSION: A 6-month kMCT supplement improved WM energy supply in MCI by increasing ketone uptake in WM fascicles. The significant positive association with processing speed suggests that ketones may have a role in myelin integrity in MCI.
© 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.

Entities:  

Keywords:  Alzheimer's disease; acetoacetate; beta‐hydroxybutyrate; brain metabolism; diffusion MRI; fascicle; glucose; ketone; medium chain triglyceride; mild cognitive impairment; positron emission tomography imaging; processing speed; tractography; tractometry; white matter

Year:  2021        PMID: 34869825      PMCID: PMC8596139          DOI: 10.1002/trc2.12217

Source DB:  PubMed          Journal:  Alzheimers Dement (N Y)        ISSN: 2352-8737


BACKGROUND

White matter (WM) undergoes axonal degeneration and demyelination in Alzheimer's disease (AD). , WM microstructural deterioration is also observed in specific brain regions in mild cognitive impairment (MCI). , AD is characterized by a chronic brain glucose deficit, which is already present in older people years before the onset of cognitive decline associated with AD. , WM energy supply is crucial for adequate axonal function in part because oligodendrocytes need a considerable amount of energy for dynamic remodeling of myelin throughout life. Hence, the gradual brain glucose deficit that begins during aging may lead to declining myelin energy metabolism, myelin loss, and impaired network connectivity, thereby contributing to cognitive dysfunction. Ketones (acetoacetate and β‐hydroxybutyrate) are the main alternative energy substrate to glucose for the brain. In infants, ketones are not only a brain energy substrate but are also the primary substrates for myelin synthesis. Recent results show that WM metabolic deterioration in AD and MCI is specific to glucose and does not involve ketones. Rescuing the brain energy deficit by providing ketones is an emerging therapeutic strategy for aging‐associated cognitive decline and has shown promise in several randomized trials. , The Brain Energy Fitness, Imaging and Cognition (BENEFIC) trial conducted in individuals with MCI showed improved measures of episodic memory, language, executive function, and processing speed after the 6‐month ketogenic intervention as well as improved cortical energy metabolism specific to increased ketone uptake. WM analysis and the association to cognitive data from the BENEFIC trial has not previously been reported and is the focus of the present report. Specific WM fascicles were targeted instead of WM as a whole because WM glucose hypometabolism was reported to be specific to limbic regions in AD. The primary aim of this study was to investigate in the BENEFIC trial imaging dataset whether a ketogenic supplement consumed for 6 months improved ketone metabolism by WM fascicles. The secondary aims were to assess whether WM glucose metabolism changed, whether WM ketone metabolism was associated with any improvement in cognitive function, and whether the ketogenic intervention impacted WM structural properties. WM energy metabolism was measured by positron emission tomography (PET) using 11C‐acetoacetate (for ketones) and 18F‐fluorodeoxyglucose (for glucose).

RESEARCH IN CONTEXT

Systematic review: We assessed all peer‐reviewed articles available on PubMed about ketogenic intervention and white matter (WM) analysis. No published studies assessing WM measurements after a ketogenic intervention in the Alzheimer's disease spectrum were found. Interpretation: This randomized controlled trial demonstrated for the first time that a 6‐month ketogenic supplementation improved WM energy supply in mild cognitive impairment, with a nearly 3‐fold increase of ketone uptake. Several measures of processing speed improved directly with both the increase in WM ketone supply globally and in individual fascicles, most importantly the fornix. This association suggests that ketones may have a role in myelin integrity in older people. Future directions: The impact of a long‐term ketogenic supplementation on myelin density should be investigated to better understand the role of ketones in myelin integrity and cognition in older people.

METHODS

Participants

The BENEFIC trial (identification number NCT02551419 at ClinicalTrials.gov) was approved by our institutional ethical committee (CIUSSS de l'Estrie–CHUS, Sherbrooke, Quebec, Canada) and informed written consent was obtained from all participants before enrollment (Table 1). Inclusion criteria were male or female aged ≥55 years and the presence of objective cognitive decline (MCI), based on the criteria of Petersen. Specifically, MCI criteria were: subjective memory complaint plus cognitive impairment in one or more domains of a neuropsychological tests battery compared to appropriate normative data (≥1.5 standard deviation less than the mean), a Montreal Cognitive Assessment (MoCA) score of 18–26/30 or Mini‐Mental State Examination (MMSE) score of ≥24/30, no evidence of probable or possible AD or depression, and full autonomy for daily living activities. Exclusion criteria are fully described in Fortier et al. The present cohort included both amnestic and non‐amnestic MCI. Cognitive and depression scores, physical autonomy, and blood assessments were within the normal range at baseline as detailed in Fortier et al.
TABLE 1

Clinical data of participants at enrollment

Placebo (n = 16)kMCT (n = 16–17)*Intergroup P value†
Age (y)75.4 ± 6.674.2 ± 6.3.600
Sex (M/F)6/109/8.491
APOE ε4 (+) (%)7/16 (44%)5/16 (31%).716
Education (y)12.4 ± 3.513.1 ± 3.6.609
MMSE (/30)26.7 ± 2.427.7 ± 2.3.126
MoCA (/30)22.1 ± 2.423.1 ± 3.4.177

Abbreviations: APOE, apolipoprotein E; kMCT, ketogenic medium chain triglyceride; MMSE, Mini‐Mental State Examination; MoCA, Montreal Cognitive Assessment score.

* APOE genotype unavailable for one participant.

† Statistical analysis was made using Mann‐Whitney test or Fisher exact test (sex and APOE ε4 status).

Clinical data of participants at enrollment Abbreviations: APOE, apolipoprotein E; kMCT, ketogenic medium chain triglyceride; MMSE, Mini‐Mental State Examination; MoCA, Montreal Cognitive Assessment score. * APOE genotype unavailable for one participant. † Statistical analysis was made using Mann‐Whitney test or Fisher exact test (sex and APOE ε4 status).

Experimental design

Participants were randomized to the ketogenic medium chain triglyceride (kMCT) or placebo group. Before starting the intervention, they underwent a dual‐tracer PET and separate magnetic resonance imaging (MRI) acquisition of the brain, plus a neurocognitive battery. A second and final dual‐tracer PET and MRI brain acquisition, and the neurocognitive battery were performed during the final week of the sixth month of the intervention (post‐intervention). The kMCT and placebo drinks were prepared as previously described. Briefly, the kMCT drink was an emulsion containing 60% caprylic acid and 40% capric acid in lactose‐free skim milk and provided 30 g/day of kMCT in a 250 mL bottle. The placebo drink contained high‐oleic acid sunflower oil and was indistinguishable from the kMCT drink. During the first 2 weeks of the intervention, the volume to be consumed was increased from 50 mL/day to the final dose of 250 mL/day to help minimize kMCT‐related gastrointestinal side effects.

Cognitive assessment

Testing and scoring cognition were double‐blinded. Tests for episodic memory, executive function, language, and attention and processing speed domains were reported in Fortier et al. All test scores were normalized and averaged to generate four composite Z‐scores, which were the first cognitive outcomes analyzed in the current study. Measures of processing speed were the Trail Making (visual scanning, number sequencing, letter sequencing, and motor speed) and Stroop Color and Word Interference tests from the Delis‐Kaplan Executive Function System, and the Digit Symbol Substitution test from the Wechsler Adult Intelligence Scale, all of which were used for secondary analysis in the current study. No learning effect was expected after the 6‐month period for most of the selected tests but alternative versions for the two memory tests were used for the post‐intervention assessment.

Image acquisition

The MRI protocol was acquired on a 3 Tesla Philips Ingenia system and included a 3D T1‐weighted sequence (duration = 6 minutes, repetition time = 7.9 ms, echo time = 3.5 ms, matrix size = 240 × 240 × 160 mm, flip angle = 8°, and 1 mm isotropic voxels), followed by high angular resolution diffusion imaging acquisition with parallel imaging SENSE 2 (duration = 11 minutes, repetition time = 11 seconds, echo time = 100 ms, matrix size = 128 × 128 × 78 mm, 1.8 mm isotropic voxels, 60 directions, b = 1500 s/mm2), and, one blip‐up and one blip‐down b = 0 s/mm2 acquisition to correct for distortions. The MRI protocol was followed on the same day by a dual‐tracer PET session , on a PET/CT Philips Gemini system, in dynamic list mode. First, 11C‐acetoacetate (AcAc) was injected for an acquisition of 10 minutes, followed by a 1‐hour wash‐out period to ensure residual 11C was negligible. 18F‐flurodeoxyglucose (FDG) was then injected and the acquisition started 30 minutes post‐injection and lasted for 30 minutes. A series of blood samples were taken during acquisitions and used to correct image‐derived input functions. FDG plasma input functions were used also to verify baseline radioactivity after the AcAc scan. Plasma glucose was measured with a glucose assay (Siemens Healthcare Diagnostics) and plasma ketones were measured as previously described.

Image analysis

Diffusion MRI

All image processing steps were blinded. Preprocessing and processing of diffusion‐weighted images were performed as previously described using the TractoFlow pipeline. Diffusion tensor imaging (DTI) measures (fractional anisotropy, mean, radial and axial diffusivities) were computed and free‐water‐corrected to reduce partial volume effects of the cerebrospinal fluid (CSF) associated with aging. , Fiber orientation distribution functions were computed , and the apparent fiber density, hereafter “fiber density,” at each fixel (specific fiber direction) was computed. The signal in a fixel is proportional to the volume of axons aligned in that direction. WM masks were corrected for white matter hyperintensities (WMH) using an average T1 template registration strategy. Local probabilistic tractography was performed to reconstruct whole‐brain tractograms, robust to crossing fibers. Nine fascicles of interest, the ones generally reported with microstructural alteration in AD, , were extracted. The WM query language method was used to automatically extract the two posterior segments of the cingulum (parahippocampal and posterior cingulate). The RecoBundlesX algorithm , was used to extract the genu and splenium of the corpus callosum, arcuate, inferior fronto‐occipital, inferior longitudinal, and uncinate fasciculi. Due to its high curvature and location next to lateral ventricles contaminating voxels with CSF, the fornix was reconstructed using a separate automated fascicle‐specific approach.

PET

PET images were analyzed as previously described , using PMOD 3.807 and its kinetic modeling tool PXMOD. Briefly, the Patlak method was used to quantify the cerebral metabolic rate (μmol/100 g/min; referred to hereafter as “uptake”), and voxel‐wise maps were generated for FDG and AcAc. Input functions and voxel‐wise uptake maps were partial volume‐corrected. Uptake maps were then co‐registered to diffusion MRI data as described previously using Advanced Normalization Tools (ANTs).

Tractometry

The quantification of PET (Figure 1 and Video 1 in supporting information) and diffusion measures in each fascicle was done using a tractometry pipeline. FDG and AcAc uptake, free‐water, fiber density, and free‐water‐corrected DTI maps were inputs for the pipeline. Mean values were calculated for all fascicles of interest. Fascicles were divided into five sections to produce a fascicle profile that better captured ketone and glucose uptake in the extremities, close to gray matter, compared to the middle of the fascicles. ,
FIGURE 1

Whole‐brain white matter tractograms from a sample participant in the ketogenic medium chain triglyceride (kMCT) group before (PRE) and after (POST) the 6‐month intervention. Streamlines are colored according to their acetoacetate metabolic rate (μmol/g/min). Subsets of 10,000 streamlines per whole‐brain tractogram are shown.

Whole‐brain white matter tractograms from a sample participant in the ketogenic medium chain triglyceride (kMCT) group before (PRE) and after (POST) the 6‐month intervention. Streamlines are colored according to their acetoacetate metabolic rate (μmol/g/min). Subsets of 10,000 streamlines per whole‐brain tractogram are shown.

Statistical analysis

Complete PET and diffusion MRIs were available for n = 16 placebo and n = 17 kMCT participants. Results are presented as the mean ± standard deviation, unless otherwise mentioned. Changes in imaging measures after the 6‐month intervention are expressed as percentage change from baseline. All statistical analyses were performed using SPSS 25.0 software. Because assumptions of homogeneity and normality of the variance were not met for some fascicles, non‐parametric tests were used without correction for multiple comparisons. Intragroup changes (pre‐ vs. post‐intervention) were analyzed with the Wilcoxon matched‐pairs signed rank test and the Mann‐Whitney test was used for intergroup comparison of changes in measures (placebo vs. kMCT). For fascicle profiles, pre‐ and post‐ketone uptake measures were set as repeated measures with a general linear model to assess the effect of the intervention along the sections of each fascicle. Correlations were performed to assess a possible association between fascicle ketone uptake and the four cognitive composite scores (episodic memory, language, executive function, and attention and processing speed combined), as well as between bothPET tracer uptake and fiber density. P < .05 was set as the threshold for statistical significance.

RESULTS

Clinical data

At baseline, both groups were of similar age, male‐to‐female ratio, apolipoprotein E ε4 status, and education. MMSE and MoCA scores were not significantly different between groups (Table 1). Details of the cognitive scores and protocol compliance were previously reported in Fortier et al. Briefly, 75% of participants completed the intervention. All completers were protocol compliant, that is, consumed a mean of 90% of the planned daily dose as measured by return bottle count. No severe adverse effects were observed. Some gastrointestinal effects were noted for some participants but were mostly transitory.

Fascicle‐based ketone uptake

At baseline, plasma ketones and fascicle ketone uptake were similar between groups (Table 2). After the 6‐month intervention, mean ketone uptake was increased by 2.5‐ to 3.2‐fold in all nine fascicles of interest in the kMCT group (Figure 2), with the highest mean increase in ketone uptake in the fornix. Mean fascicle ketone uptake was unchanged in the placebo group, and the pre‐ to post‐intervention increase in ketone uptake was significantly higher in all fascicles in the kMCT group compared to placebo (P = .002 to .013; Table 2).
TABLE 2

White matter fascicle‐based ketone uptake (AcAc) before (Pre) and after (Post) the 6‐month intervention

Placebo (n = 16)kMCT (n = 17)Δ placebo vs. Δ kMCT
PrePost P value†PrePost P value† P value‡
Plasma ketones (μM)*
AcAc136 ± 79110 ± 52.515124 ± 54286 ± 142<.001<.001
β‐HB212 ± 112177 ± 89.525210 ± 136572 ± 325<.001<.001
Fascicle AcAc metabolic rate (μmol/g/min)
PCC_L27.7 ± 20.621.8 ± 14.5.59727.5 ± 17.649.8 ± 27.5.002.013
PCC_R27.7 ± 17.622.9 ± 16.4.59726.5 ± 15.655.2 ± 31.5<.001.002
PHC_L24.5 ± 17.919.3 ± 14.1.49522.7 ± 16.049.7 ± 27.3<.001.002
PHC_R24.5 ± 17.319.8 ± 14.5.49521.9 ± 13.247.1 ± 25.0<.001.002
FX_L22.4 ± 12.319.5 ± 13.2.66919.4 ± 10.843.7 ± 24.5<.001.004
FX_R20.9 ± 13.718.1 ± 12.2.82117.4 ± 10.039.9 ± 24.7<.001.002
AF_L21.3 ± 15.918.1 ± 12.2.78220.3 ± 12.744.7 ± 23.5<.001.003
AF_R20.7 ± 13.718.3 ± 12.3.86020.3 ± 12.843.6 ± 22.9<.001.004
CC219.9 ± 12.918.4 ± 13.0.90019.2 ± 11.443.2 ± 22.6<.001.002
CC724.6 ± 17.019.5 ± 12.9.49523.1 ± 14.047.5 ± 24.4<.001.004
IFOF_L23.7 ± 16.520.2 ± 13.9.70622.3 ± 13.748.3 ± 24.3<.001.004
IFOF_R23.5 ± 16.120.6 ± 13.9.82123.1 ± 14.450.0 ± 25.8<.001.004
ILF_L23.7 ± 17.020.0 ± 13.6.70622.1 ± 13.548.8 ± 25.0<.001.002
ILF_R23.9 ± 16.120.5 ± 14.0.66822.8 ± 14.049.9 ± 25.3<.001.003
UF_L23.4 ± 15.520.9 ± 14.3.94022.7 ± 14.149.6 ± 25.2<.001.004
UF_R23.1 ± 15.920.9 ± 14.1>.99923.2 ± 14.450.8 ± 26.9<.001.003

Abbreviations: AcAc, 11C‐acetoacetate; AF, arcuate fasciculus; β‐HB, β‐hydroxybutyrate; CC2, genu of the corpus callosum; CC7, splenium of the corpus callosum; FX, fornix; IFOF, inferior fronto‐occipital fasciculus; ILF, inferior longitudinal fasciculus; kMCT, ketogenic medium chain triglyceride; PCC, posterior cingulate segment of the cingulum; PHC, parahippocampal segment of the cingulum; UF, uncinate fasciculus.

* Plasma ketones were measured at baseline after a 6‐h fast (Pre) and 2 h after the kMCT supplement (Post).

† Statistical analysis using Wilcoxon matched‐pair signed rank test.

‡ Statistical analysis using Mann‐Whitney test.

FIGURE 2

Left, White matter fascicle‐based changes (left hemisphere only) in ketone uptake in the kMCT group after the 6‐month intervention. Median ketone uptake was increased in all nine fascicles of interest after the intervention (refer to Table 2 for P values). Note that the median and interquartile range are illustrated for each fascicle, whereas mean values are reported in the text and tables. Right, Glass brain representations show the nine fascicles of interest. Fascicle colors correspond to the points in the left panel. AF, arcuate fasciculus; CC2, genu of the corpus callosum; CC7, splenium of the corpus callosum; FX, fornix; IFOF, inferior fronto‐occipital fasciculus; ILF, inferior longitudinal fasciculus; kMCT, ketogenic medium chain triglyceride; PCC, posterior cingulate segment of the cingulum; PHC, parahippocampal segment of the cingulum; UF, uncinate fasciculus

White matter fascicle‐based ketone uptake (AcAc) before (Pre) and after (Post) the 6‐month intervention Abbreviations: AcAc, 11C‐acetoacetate; AF, arcuate fasciculus; β‐HB, β‐hydroxybutyrate; CC2, genu of the corpus callosum; CC7, splenium of the corpus callosum; FX, fornix; IFOF, inferior fronto‐occipital fasciculus; ILF, inferior longitudinal fasciculus; kMCT, ketogenic medium chain triglyceride; PCC, posterior cingulate segment of the cingulum; PHC, parahippocampal segment of the cingulum; UF, uncinate fasciculus. * Plasma ketones were measured at baseline after a 6‐h fast (Pre) and 2 h after the kMCT supplement (Post). † Statistical analysis using Wilcoxon matched‐pair signed rank test. ‡ Statistical analysis using Mann‐Whitney test. Left, White matter fascicle‐based changes (left hemisphere only) in ketone uptake in the kMCT group after the 6‐month intervention. Median ketone uptake was increased in all nine fascicles of interest after the intervention (refer to Table 2 for P values). Note that the median and interquartile range are illustrated for each fascicle, whereas mean values are reported in the text and tables. Right, Glass brain representations show the nine fascicles of interest. Fascicle colors correspond to the points in the left panel. AF, arcuate fasciculus; CC2, genu of the corpus callosum; CC7, splenium of the corpus callosum; FX, fornix; IFOF, inferior fronto‐occipital fasciculus; ILF, inferior longitudinal fasciculus; kMCT, ketogenic medium chain triglyceride; PCC, posterior cingulate segment of the cingulum; PHC, parahippocampal segment of the cingulum; UF, uncinate fasciculus Ketone uptake along fascicle section profiles was significantly increased post‐intervention in the kMCT group (P < .001; Figure S1 in supporting information). This increase was similar in the middle section (section 3) compared to tail section (section 5) for all nine fascicles of interest (P = .610 to .946). The increase of ketone uptake in the kMCT group was similar in the total WM and total cortex, 2.9‐ versus 2.5‐fold, respectively (Table S1 in supporting information; P = .865). The change in plasma ketones was positively associated with the change in total WM ketone uptake (Figure S2 in supporting information; r = +0.84; P < .001).

Association of fascicle ketone uptake with processing speed

At baseline, processing speed Z‐score was similar between groups (P = .544). In the kMCT group after the 6‐month intervention, the composite Z‐score of processing speed was improved in direct relation to the increase in ketone uptake both in total WM (r = +0.52; P = .041) and in all fascicles individually (r = +0.46 to +0.61; P = .014 to .072), except for the posterior cingulate segment of the cingulum (Figure 3 and Table S2 in supporting information). In the placebo group, post‐intervention changes in processing speed were inversely related to ketone uptake in total WM (r = –0.53; P = .043) and in individual fascicles (Table S2), a relationship not found at baseline. Slopes between the two groups were significantly different for all nine fascicles of interest (P = .003 to .028). The strongest association between the improvement in processing speed Z‐score and the increase in ketone uptake in the kMCT group was in the fornix (r = +0.61; P = .014). Pre‐intervention, ketone uptake in the fornix also had the strongest association with processing speed Z‐score when both treatment groups were combined (r = +0.44; P = .010; data not shown).
FIGURE 3

Left, Composite Z‐score of processing speed was improved in direct association with the mean increase of ketone uptake in total white matter (r = +0.52; P = .041) and in several fascicles in the kMCT group after the 6‐month intervention. Refer to Table S2 for P values. * = P < .05. Fascicles from the left hemisphere are presented. Right, The glass brain representation shows all fascicles for which the association between change in ketone uptake and processing speed was significant. Fascicle colors correspond to the bars in the panel on the left. AF, arcuate fasciculus; CC2, genu of the corpus callosum; CC7, splenium of the corpus callosum; FX, fornix; IFOF, inferior fronto‐occipital fasciculus; ILF, inferior longitudinal fasciculus; PCC, posterior cingulate segment of the cingulum; PHC, parahippocampal segment of the cingulum; UF, uncinate fasciculus; WM, white matter

Left, Composite Z‐score of processing speed was improved in direct association with the mean increase of ketone uptake in total white matter (r = +0.52; P = .041) and in several fascicles in the kMCT group after the 6‐month intervention. Refer to Table S2 for P values. * = P < .05. Fascicles from the left hemisphere are presented. Right, The glass brain representation shows all fascicles for which the association between change in ketone uptake and processing speed was significant. Fascicle colors correspond to the bars in the panel on the left. AF, arcuate fasciculus; CC2, genu of the corpus callosum; CC7, splenium of the corpus callosum; FX, fornix; IFOF, inferior fronto‐occipital fasciculus; ILF, inferior longitudinal fasciculus; PCC, posterior cingulate segment of the cingulum; PHC, parahippocampal segment of the cingulum; UF, uncinate fasciculus; WM, white matter Increased fascicle ketone uptake was not associated with episodic memory, language, or executive function composite scores. Therefore, further analyses were restricted to measures of processing speed. In the kMCT group, improved processing speed (decreased time taken) post‐intervention on the motor speed task of the Trail Making Test was significantly inversely associated with increased ketone uptake in total WM (r = –0.50; P = .043) and in all fascicles individually (Table S3 in supporting information). No such association was observed for the placebo group. Post‐intervention, processing speed was 14% slower on the visual scanning task of the Trail Making Test for the placebo group (pre: 30 seconds and post: 34 seconds; P = .040) but remained unchanged in the kMCT group (P = .922). In the kMCT group, improvement on the visual scanning task of the Trail Making Test was also associated with increased ketone uptake in total WM (r = –0.53; P = .036) and in the fornix, genu of the corpus callosum, arcuate, inferior fronto‐occipital, and inferior longitudinal fasciculi (data not shown).

Fascicle‐based diffusion measures

No difference in diffusion measures pre‐ to post‐intervention was observed between both groups. After the 6‐month intervention, the fiber density was 8% to 14% lower in most fascicles of both groups, except for the fornix, and parahippocampal and posterior cingulate segments of the cingulum (Table S4 in supporting information). The splenium of the corpus callosum had the greatest decrease in fiber density. In contrast, fiber density was increased by 11% to 18% post‐intervention in both groups in the left parahippocampal and posterior cingulate segments of the cingulum, respectively. Free‐water‐corrected radial diffusivity was significantly increased in several fascicles post‐intervention in both groups but was reduced specifically in the posterior cingulate segment of the cingulum (P < .001 to .011; data not shown). Free‐water‐corrected fractional anisotropy was increased by 15% to 18% in the posterior cingulate segment of the cingulum in both groups (P < .001 to.003; data not shown). Post‐intervention, both groups had 4% to 23% higher free‐water in all fascicles, especially the parahippocampal segment of the cingulum, except for the left posterior cingulate segment of the cingulum and right fornix (Table S5 in supporting information).

Fascicle‐based glucose uptake and association with fiber density

No significant difference was found for fascicle glucose uptake between groups at baseline (Table S6 in supporting information). No difference in glucose uptake pre‐ to post‐intervention was found between the two treatments. Post‐intervention, mean glucose uptake was unchanged in all fascicles, except in the posterior cingulate segment of the cingulum where it was reduced by 9% to 11% in both groups (P = .009 to .044; Table S6). When combined across both groups, the change in glucose uptake was positively associated with change in fiber density in the uncinate fasciculus, fornix, and genu of the corpus callosum (r = +0.41 to +0.52; P = .003 to .028), but inversely in the posterior cingulate segment of the cingulum (r = –0.45; P = .012; Figure 4). For these significant associations, slopes were significantly non‐zero (P = .003 to .030; data not shown).
FIGURE 4

A, After the 6‐month intervention, change in mean glucose uptake was positively associated with change in fiber density in the uncinate fasciculus, fornix, and genu of the corpus callosum, but inversely associated in the posterior cingulate segment of the cingulum. Data from both the placebo (○) and kMCT (■) groups were combined because no significant treatment effect was found for these variables. * = P < .05. Fascicles from the left (L) hemisphere are presented. B, The glass brain representation shows all fascicles for which the association was significant. Fascicle colors correspond to the bars in panel A. C‐F, Scatter plots of significant associations between change in glucose uptake and fiber density. AF, arcuate fasciculus; CC2, genu of the corpus callosum; CC7, splenium of the corpus callosum; FX, fornix; IFOF, inferior fronto‐occipital fasciculus; ILF, inferior longitudinal fasciculus; PCC, posterior cingulate segment of the cingulum; PHC, parahippocampal segment of the cingulum; UF, uncinate fasciculus

A, After the 6‐month intervention, change in mean glucose uptake was positively associated with change in fiber density in the uncinate fasciculus, fornix, and genu of the corpus callosum, but inversely associated in the posterior cingulate segment of the cingulum. Data from both the placebo (○) and kMCT (■) groups were combined because no significant treatment effect was found for these variables. * = P < .05. Fascicles from the left (L) hemisphere are presented. B, The glass brain representation shows all fascicles for which the association was significant. Fascicle colors correspond to the bars in panel A. C‐F, Scatter plots of significant associations between change in glucose uptake and fiber density. AF, arcuate fasciculus; CC2, genu of the corpus callosum; CC7, splenium of the corpus callosum; FX, fornix; IFOF, inferior fronto‐occipital fasciculus; ILF, inferior longitudinal fasciculus; PCC, posterior cingulate segment of the cingulum; PHC, parahippocampal segment of the cingulum; UF, uncinate fasciculus

DISCUSSION

This is the first study to report the impact of a ketogenic intervention on WM structure and energy metabolism in humans. We show that a 6‐month kMCT supplement improved WM energy supply with a nearly 3‐fold increase in ketone uptake but with no significant effect on glucose uptake. The increased ketone uptake was present in all WM fascicles assessed and was as important in the deep WM as in the fascicle endpoints in gray matter. Processing speed improvement was positively associated with increased WM ketone uptake globally and in individual fascicles, most importantly in the fornix, suggesting that ketones may have a role in myelin integrity in MCI. In MCI, increased fiber density was specific to the posterior cingulum, which also had declining glucose metabolism during the 6‐month study period. In the kMCT group, ketone uptake increased over 6 months in all fascicles analyzed (Figure 1, 2, and Video 1). The fornix had the highest increase in mean ketone uptake post‐intervention, which may in part be linked to its lower ketone and glucose uptake at baseline. This increase in ketone availability to the fornix may potentially be beneficial to limit the early decline of structural integrity of the fornix during aging. A global 2.5‐fold increase of ketone uptake was also found for the cortex (Table S1), an increase that was not significantly different from the 2.9‐fold increase in total WM. Clearly, in MCI, WM avidly consumes ketones when they are available. In the kMCT group, processing speed composite Z‐score improved in association with the increase of ketone uptake in almost all individual fascicles as well as in WM as a whole (Figure 3). This suggests that information processing is probably linked to global structural connectivity in MCI, rather than to a specific fascicle, which agrees with previous studies in older adults. , For specific cognitive tests, the strongest association with increased ketone uptake was for the motor speed task of the Trail Making Test, a nearly pure measure of processing speed. Degeneration of myelin lipids associated with aging has been proposed to provide fatty acids or ketones as an energetic substrate for neurons. Processing speed is directly linked to myelin integrity because conduction of action potentials is proportional to the thickness of myelin sheaths. Declining processing speed is a key deficit in multiple sclerosis, a disease with widespread demyelination of the WM. Hence, improved processing speed scores may have been a consequence of increased myelin density after the ketogenic intervention. Processing speed may also have improved due to increased intra‐axonal mitochondrial production of adenosine triphosphate, resulting from the increase in ketone supply to the brain. An important part of the energy used by the brain is to maintain information processing speed through impulse propagation. In the BENEFIC trial, positive correlations between plasma ketones and tests of episodic memory, executive function, and language were found, but not with processing speed. This reinforces the essential role of WM in processing speed for which ketones may act as an important structural and energy substrate. In contrast to the kMCT group, in the placebo group, an inverse association was found between WM ketone uptake and processing speed. Slower processing speed in the placebo group may be attributable to disease progression over the 6 months. Indeed, WM pathology in MCI is associated with impaired processing speed. There was no significant association between ketone uptake by the fornix and memory, but there was a strong positive correlation with processing speed in the kMCT group. The microstructure of the fornix has previously been reported to be associated with processing speed but not with memory in older adults and in epilepsy, suggesting a role of the fornix beyond memory function. The 6‐month kMCT supplement had no significant effect on structural WM measures. Physical activity interventions of a 1‐year duration also do not seem to impact WM microstructure in older adults and MCI. We show here that, as opposed to other fascicles, the fiber density of the posterior cingulum increased in both groups (Table S4). This supports the “network failure” theory, , which proposes that in the prodromal phase of AD, the posterior default mode network (a key processing hub) starts compensating for declining function of other brain networks, becomes overloaded, and starts to shift its processing load to related networks, resulting in increased connectivity between the posterior default mode network and other hubs. Structural connectivity changes associated with cognitive decline may therefore follow a non‐linear trajectory for some specific networks. We show here a decline in glucose uptake over 6 months specifically in the posterior cingulate segment of the cingulum in both groups (Table S6). In the kMCT group, the increase of ketone uptake and decrease of glucose uptake in this fascicle were not significantly correlated (data not shown), so it seems possible that disease progression over the 6 months could have been linked specifically to declining glucose uptake in the posterior cingulate segment of the cingulum. The posterior cingulate segment of the cingulum had the highest glucose uptake at baseline (62% higher than the fornix), which may make this region more vulnerable to declining energy (glucose) metabolism during aging. The increase in ketone uptake post‐intervention was also the lowest in the posterior cingulate segment of the cingulum. This would make it more difficult for ketones to compensate for impaired glucose uptake in posterior cingulate segment of the cingulum during MCI. Other tractography studies show that the posterior cingulum has lower glucose uptake and fiber density in MCI compared to controls, suggesting it is a particularly vulnerable fascicle when MCI develops. A limitation of the present study was the small sample size for assessing the relationships to cognitive outcomes. Although WMH were eliminated for robust fascicle reconstruction, another limitation was the inability to segment these lesions and establish whether both groups had a similar cerebrovascular burden. However, in terms of cardiovascular risk factors, both groups had similar blood pressure and plasma cholesterol at baseline. WMH regional load may have affected the cerebral metabolic rate of PET tracers, but the relationship between WM ketone uptake and processing speed was still highly significant. In future studies, including fluid‐attenuated inversion recovery (FLAIR) images will be important for automated segmentation of WMH. Because of the importance of myelin for information processing and its link to ketone metabolism, assessment of the myelin content would also be recommended in the future when ketogenic or other energetic interventions are used. The lack of specificity of radial diffusivity to myelin requires a more sophisticated MRI sequence, such as the inhomogeneous magnetization transfer data, more specific to myelin. In conclusion, we show that a 6‐month kMCT supplement increased ketone supply in WM fascicles in MCI, with an equivalent effect in deep WM as in fascicle gray matter endpoints. Several improved measures of processing speed were directly associated with increased WM ketone supply globally and in individual fascicles, most importantly in the fornix. These data also support the idea of a posterior cingulum vulnerability at the MCI stage. The impact of a long‐term ketogenic supplementation on myelin density should be investigated to better understand the role of ketones in myelin integrity and cognition in MCI.

CONFLICTS OF INTEREST

SCC has consulted for or received travel honoraria or test products from Nestlé Health Science, German Nutrition Society, Bulletproof, Cerecin, Abbott, Servier, Pro‐Diet and Abitec. SCC is the founder and director of Senotec Ltd. MD is CSO and shareholder of Imeka Solutions Inc and MR is consultant for Imeka Solutions Inc. MD and MR were part of advisory boards for INmune Bio Inc and MD received consulting fees from INmune Bio Inc. All other authors have nothing to disclose. Supporting material Click here for additional data file. Supporting material Click here for additional data file. Supporting material Click here for additional data file.
  46 in total

1.  Robust determination of the fibre orientation distribution in diffusion MRI: non-negativity constrained super-resolved spherical deconvolution.

Authors:  J-Donald Tournier; Fernando Calamante; Alan Connelly
Journal:  Neuroimage       Date:  2007-02-21       Impact factor: 6.556

Review 2.  Recognition of white matter bundles using local and global streamline-based registration and clustering.

Authors:  Eleftherios Garyfallidis; Marc-Alexandre Côté; Francois Rheault; Jasmeen Sidhu; Janice Hau; Laurent Petit; David Fortin; Stephen Cunanne; Maxime Descoteaux
Journal:  Neuroimage       Date:  2017-07-13       Impact factor: 6.556

Review 3.  Axo-myelinic neurotransmission: a novel mode of cell signalling in the central nervous system.

Authors:  Ileana Micu; Jason R Plemel; Andrew V Caprariello; Klaus-Armin Nave; Peter K Stys
Journal:  Nat Rev Neurosci       Date:  2017-11-09       Impact factor: 34.870

4.  TractoFlow: A robust, efficient and reproducible diffusion MRI pipeline leveraging Nextflow & Singularity.

Authors:  Guillaume Theaud; Jean-Christophe Houde; Arnaud Boré; François Rheault; Felix Morency; Maxime Descoteaux
Journal:  Neuroimage       Date:  2020-05-21       Impact factor: 6.556

5.  Brain glucose and acetoacetate metabolism: a comparison of young and older adults.

Authors:  Scott Nugent; Sebastien Tremblay; Kewei W Chen; Napatkamon Ayutyanont; Auttawut Roontiva; Christian-Alexandre Castellano; Melanie Fortier; Maggie Roy; Alexandre Courchesne-Loyer; Christian Bocti; Martin Lepage; Eric Turcotte; Tamas Fulop; Eric M Reiman; Stephen C Cunnane
Journal:  Neurobiol Aging       Date:  2013-12-01       Impact factor: 4.673

6.  Energetic and nutritional constraints on infant brain development: implications for brain expansion during human evolution.

Authors:  Stephen C Cunnane; Michael A Crawford
Journal:  J Hum Evol       Date:  2014-06-11       Impact factor: 3.895

Review 7.  Pathways to Brain Aging and Their Modifiers: Free-Radical-Induced Energetic and Neural Decline in Senescence (FRIENDS) Model - A Mini-Review.

Authors:  Naftali Raz; Ana M Daugherty
Journal:  Gerontology       Date:  2017-09-01       Impact factor: 5.140

Review 8.  Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer's disease.

Authors:  Stephen C Cunnane; Alexandre Courchesne-Loyer; Valérie St-Pierre; Camille Vandenberghe; Tyler Pierotti; Mélanie Fortier; Etienne Croteau; Christian-Alexandre Castellano
Journal:  Ann N Y Acad Sci       Date:  2016-01-14       Impact factor: 5.691

Review 9.  Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing.

Authors:  Stephen C Cunnane; Mark J Millan; Eugenia Trushina; Cecilie Morland; Alessandro Prigione; Gemma Casadesus; Zane B Andrews; M Flint Beal; Linda H Bergersen; Roberta D Brinton; Suzanne de la Monte; Anne Eckert; Jenni Harvey; Ross Jeggo; Jack H Jhamandas; Oliver Kann; Clothide Mannoury la Cour; William F Martin; Gilles Mithieux; Paula I Moreira; Michael P Murphy; Klaus-Armin Nave; Tal Nuriel; Stéphane H R Oliet; Frédéric Saudou; Mark P Mattson; Russell H Swerdlow
Journal:  Nat Rev Drug Discov       Date:  2020-07-24       Impact factor: 84.694

10.  Investigating white matter fibre density and morphology using fixel-based analysis.

Authors:  David A Raffelt; J-Donald Tournier; Robert E Smith; David N Vaughan; Graeme Jackson; Gerard R Ridgway; Alan Connelly
Journal:  Neuroimage       Date:  2016-09-14       Impact factor: 6.556

View more
  3 in total

Review 1.  Molecular Mechanisms Underlying the Bioactive Properties of a Ketogenic Diet.

Authors:  Mari Murakami; Paola Tognini
Journal:  Nutrients       Date:  2022-02-13       Impact factor: 5.717

2.  Multimodal strategy to rescue the brain in mild cognitive impairment: Ketogenic oral nutrition supplementation with B vitamins and aerobic exercise.

Authors:  Stephen C Cunnane; Russell H Swerdlow; Marco Inzitari; Gloria Olaso-Gonzalez; José Viña
Journal:  Eur J Clin Invest       Date:  2022-05-12       Impact factor: 5.722

Review 3.  Traditional and Medical Applications of Fasting.

Authors:  Francesco Visioli; Carla Mucignat-Caretta; Francesca Anile; Stefan-Alexandru Panaite
Journal:  Nutrients       Date:  2022-01-19       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.